STEAP2 and prostate cancer: Many publications have underscored the attractiveness of STEAP2 for prostate cancer targeting, not only because of its favorable expression profile, but also because it is reported to be a driver of prostate cancer proliferation, indicating that it may not be easily dispensable as a means of resistance (6, 19, 20).